Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW.

Cancer Res. 2013 Sep 15;73(18):5775-86. doi: 10.1158/0008-5472.CAN-13-1318. Epub 2013 Jul 25.

2.

The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ.

Blood. 2011 Nov 10;118(19):5250-4. doi: 10.1182/blood-2011-05-349191. Epub 2011 Sep 8.

3.

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ.

J Clin Invest. 2011 Jan;121(1):396-409. doi: 10.1172/JCI35721. Epub 2010 Dec 13. Erratum in: J Clin Invest. 2011 Mar 1;121(3):1222.

4.

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T.

Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.

5.

A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.

Johnson KJ, Griswold IJ, O'Hare T, Corbin AS, Loriaux M, Deininger MW, Druker BJ.

PLoS One. 2009 Oct 13;4(10):e7439. doi: 10.1371/journal.pone.0007439.

6.

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.

Agarwal A, Bumm TG, Corbin AS, O'Hare T, Loriaux M, VanDyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, Deininger MW.

Blood. 2008 Sep 1;112(5):1960-70. doi: 10.1182/blood-2007-09-113860. Epub 2008 Jun 17.

7.

An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.

Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, Druker BJ, Corless CL, Heinrich MC, Deininger MW.

Leukemia. 2008 Dec;22(12):2269-72. doi: 10.1038/leu.2008.124. Epub 2008 May 29. No abstract available.

PMID:
18509354
8.

SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.

O'Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW.

Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5507-12. doi: 10.1073/pnas.0800587105. Epub 2008 Mar 26.

9.

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.

Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, O'Hare T, Heinrich MC, Deininger MW, Druker BJ.

Blood. 2008 Feb 15;111(4):2238-45. Epub 2007 Nov 19.

10.

Characterization of murine JAK2V617F-positive myeloproliferative disease.

Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW.

Cancer Res. 2006 Dec 1;66(23):11156-65.

11.

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.

Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW.

Mol Cell Biol. 2006 Aug;26(16):6082-93.

12.

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.

Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2239-47.

13.

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.

Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC.

Cancer Res. 2006 Jan 1;66(1):473-81.

14.

Targeted CML therapy: controlling drug resistance, seeking cure.

O'Hare T, Corbin AS, Druker BJ.

Curr Opin Genet Dev. 2006 Feb;16(1):92-9. Epub 2005 Dec 15. Review.

PMID:
16343892
15.

A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib.

Crossman LC, O'Hare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, O'Brien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MW.

Leukemia. 2005 Nov;19(11):1859-62.

PMID:
16151465
16.

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.

Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Shakespeare WC, Snodgrass J, Wardwell S, Dalgarno D, Iuliucci J, Sawyer TK, Heinrich MC, Druker BJ, Deininger MW.

Blood. 2005 Jul 1;106(1):227-34. Epub 2005 Mar 3.

17.

Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl.

Grossmann AH, Kolibaba KS, Willis SG, Corbin AS, Langdon WS, Deininger MW, Druker BJ.

FEBS Lett. 2004 Nov 19;577(3):555-62.

18.

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.

Corbin AS, Griswold IJ, La Rosée P, Yee KW, Heinrich MC, Reimer CL, Druker BJ, Deininger MW.

Blood. 2004 Dec 1;104(12):3754-7. Epub 2004 Aug 10.

19.

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.

La Rosée P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, Mauro MM, Melo JV, Deininger MW, Druker BJ.

Blood. 2004 Jan 1;103(1):208-15. Epub 2003 Aug 21.

20.

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.

Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW.

Blood. 2003 Jun 1;101(11):4611-4. Epub 2003 Feb 6.

21.
22.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R.

Leukemia. 2002 Nov;16(11):2190-6.

23.

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

Corbin AS, Buchdunger E, Pascal F, Druker BJ.

J Biol Chem. 2002 Aug 30;277(35):32214-9. Epub 2002 Jun 20.

24.

Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.

Bhat A, Johnson KJ, Oda T, Corbin AS, Druker BJ.

J Biol Chem. 1998 Nov 27;273(48):32360-8.

Supplemental Content

Loading ...
Support Center